MUC1 568 A/G genotype-dependent Cancer Antigen 15-3 levels in breast cancer patients

Clinical Biochemistry

Volumn 42, Issue 7-8, 2009, Pages 662-665

  Kruit, Adrian ^a   Tilanus Linthorst, Madeleine M ^b   Boonstra, Joke G ^b   van Schaik, Ron H N ^b   Grutters, Jan C ^a   van den Bosch, Jules M M ^a   Ruven, Henk J T ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

568 A G; Breast cancer; CA 15 3; MUC1; Single nucleotide polymorphism

Indexed keywords

ADENOSINE; CA 15-3 ANTIGEN; GUANINE; MUCIN 1;

ADULT; ARTICLE; BENIGN TUMOR; BREAST CANCER; BREAST TUMOR; CANCER PATIENT; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOASSAY; MIDDLE AGED; MUCIN-1; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 63749089983     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.11.020     Document Type: Article

References (22)

1. Berruti A., Tampellini M., Torta M., Buniva T., Gorzegno G., and Dogliotti L. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur. J. Cancer 30A 14 (1994) 2082-2084
2. Lauro S., Trasatti L., Bordin F., et al. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res. 19 4C (1999) 3511-3515
3. Molina R., Jo J., Filella X., et al. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res. 19 4A (1999) 2551-2555
4. Bast Jr. R.C., Ravdin P., Hayes D.F., et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 19 6 (2001) 1865-1878
5. Anonymous. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J. Clin. Oncol. 14 10 (1996) 2843-2877
6. Duffy M.J. Serum tumor markers in breast cancer: are they of clinical value?. Clin. Chem. 52 3 (2006) 345-351
7. Janssen R., Kruit A., Grutters J.C., Ruven H.J., Gerritsen W.B., and van den Bosch J.M. The mucin-1 568 adenosine to guanine polymorphism influences serum Krebs von den Lungen-6 levels. Am. J. Respir. Cell Mol. Biol. 34 4 (2006) 496-499
8. Kruit A., Grutters J.C., Gerritsen W.B., et al. ACE I/D-corrected Z-scores to identify normal and elevated ACE activity in sarcoidosis. Respir. Med. 101 3 (2007) 510-515
9. Kohno N., Akiyama M., Kyoizumi S., Hakoda M., Kobuke K., and Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn. J. Clin. Oncol. 18 3 (1988) 203-216
10. Kohno N., Awaya Y., Oyama T., et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am. Rev. Respir. Dis. 148 3 (1993) 637-642
11. Kirk R. Experimental design. 3 ed (1995), Brooks/Cole publishing company, Pacific Grove 177-180
12. Khatcheressian J.L., Wolff A.C., Smith T.J., et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J. Clin. Oncol. 24 31 (2006) 5091-5097
13. Shering S.G., Sherry F., McDermott E.W., O N.J., Higgins, and Duffy M.J. Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma. Cancer 83 12 (1998) 2521-2527
14. Duffy M.J., Duggan C., Keane R., et al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin. Chem. 50 3 (2004) 559-563
15. Klee G.G., and Schreiber W.E. MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen?. Arch. Pathol. Lab. Med. 128 10 (2004) 1131-1135
16. Hilgers J., von Mensdorff-Pouilly S., Verstraeten A.A., and Kenemans P. Quantitation of polymorphic epithelial mucin: a challenge for biochemists and immunologists. Scand. J. Clin. Lab. Invest. Suppl. 221 (1995) 81-86
17. Price M.R., Rye P.D., Petrakou E., et al. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996. Tumour Biol. 19 Suppl 1 (1998) 1-20
18. Ligtenberg M.J., Vos H.L., Gennissen A.M., and Hilkens J. Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J. Biol. Chem. 265 10 (1990) 5573-5578
19. Pratt W.S., Islam I., and Swallow D.M. Two additional polymorphisms within the hypervariable MUC1 gene: association of alleles either side of the VNTR region. Ann. Hum. Genet. 60 Pt 1 (1996) 21-28
20. Yang E., Hu X.F., and Xing P.X. Advances of MUC1 as a target for breast cancer immunotherapy. Histol. Histopathol. 22 8 (2007) 905-922
21. Kawaguchi T., Takazawa H., Imai S., Morimoto J., and Watanabe T. Lack of polymorphism in MUC1 tandem repeats in cancer cells is related to breast cancer progression in Japanese women. Breast Cancer Res. Treat. 92 3 (2005) 223-230
22. McGuckin M.A., Walsh M.D., Hohn B.G., Ward B.G., and Wright R.G. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum. Pathol. 26 4 (1995) 432-439